​Prof. Hiroyuki NagaseDivision of Respiratory Medicine and Allergology, Teikyo University School of MedicineProf. Hisatoshi SugiuraDepartment of Respiratory Medicine, Tohoku University Graduate School of MedicineDr. Toshihiro ShiraiDepartment of Respiratory Medicine, Shizuoka General Hospital

• Part 1 Concept of Asthma COPD overlap.- 1 Concept of Asthma COPD overlap - Japanese guideline and global trends. How was the concept of Asthma COPD overlap developed and moving forward? .- 2 Concept of treatable traits and ACO (2): Can treatable traits approach be applied into practice? .- Part 2 Epidemiology and Prognosis.- 3 Epidemiology of ACO from global data: Does the prevalence of ACO vary among global analyses? .- 4 Epidemiology of ACO defined by the JRS guidelines. What is the prevalence of ACO in Japan? .- 5 Prognosis and characteristics of ACO: What are the specific characteristics of ACO?- 6 Prognosis of COPD with asthma-like features and ACO: Is the prognosis of COPD and ACO different? .- 7 Causes of death in patients with asthma-chronic obstructive pulmonary disease overlap: Is there any difference compared to asthma?.- Part 3 Pathophysiology of ACO.- 8 Inflammatory phenotypes and potential bio-markers of ACO. What is the specific feature of ACO? .- 9 Role of Nitrosative stress: What is the potential clinical implication?.- 10 Radiographic features of ACO. How the feature is applied into practice?.- 11 Pulmonary Function of ACO: What is the role of the forced oscillation technique?.- 12 Underlying mechanism suggested by the ACO model. What is the lesson learned from the model?.- Part 4 Diagnosis of ACO.- 13 Comparison of diagnostic criteria of ACO: What is the point of difference?.- 14 Role of FeNO - How can FeNO be positioned in practice?.- 15 Role of IgE and Eosinophils: The use of type 2 biomarkers in practice.- 16 Rhinosinusitis in ACO: What is the implication of nasal comorbidity?.- Part 5 Treatment.- 17 Current evidence of treatment for asthma-COPD overlap (ACO): Is there emerging evidence of optimal therapy? .- 18 Potential treatment options for ACO, including biologics: Are there any roles of biologics?.

​Prof. Hiroyuki NagaseDivision of Respiratory Medicine and Allergology, Teikyo University School of MedicineProf. Hisatoshi SugiuraDepartment of Respiratory Medicine, Tohoku University Graduate School of MedicineDr. Toshihiro ShiraiDepartment of Respiratory Medicine, Shizuoka General Hospital

• Part 1 Concept of Asthma COPD overlap.- 1 Concept of Asthma COPD overlap - Japanese guideline and global trends. How was the concept of Asthma COPD overlap developed and moving forward? .- 2 Concept of treatable traits and ACO (2): Can treatable traits approach be applied into practice? .- Part 2 Epidemiology and Prognosis.- 3 Epidemiology of ACO from global data: Does the prevalence of ACO vary among global analyses? .- 4 Epidemiology of ACO defined by the JRS guidelines. What is the prevalence of ACO in Japan? .- 5 Prognosis and characteristics of ACO: What are the specific characteristics of ACO?- 6 Prognosis of COPD with asthma-like features and ACO: Is the prognosis of COPD and ACO different? .- 7 Causes of death in patients with asthma-chronic obstructive pulmonary disease overlap: Is there any difference compared to asthma?.- Part 3 Pathophysiology of ACO.- 8 Inflammatory phenotypes and potential bio-markers of ACO. What is the specific feature of ACO? .- 9 Role of Nitrosative stress: What is the potential clinical implication?.- 10 Radiographic features of ACO. How the feature is applied into practice?.- 11 Pulmonary Function of ACO: What is the role of the forced oscillation technique?.- 12 Underlying mechanism suggested by the ACO model. What is the lesson learned from the model?.- Part 4 Diagnosis of ACO.- 13 Comparison of diagnostic criteria of ACO: What is the point of difference?.- 14 Role of FeNO - How can FeNO be positioned in practice?.- 15 Role of IgE and Eosinophils: The use of type 2 biomarkers in practice.- 16 Rhinosinusitis in ACO: What is the implication of nasal comorbidity?.- Part 5 Treatment.- 17 Current evidence of treatment for asthma-COPD overlap (ACO): Is there emerging evidence of optimal therapy? .- 18 Potential treatment options for ACO, including biologics: Are there any roles of biologics?.

​Prof. Hiroyuki NagaseDivision of Respiratory Medicine and Allergology, Teikyo University School of MedicineProf. Hisatoshi SugiuraDepartment of Respiratory Medicine, Tohoku University Graduate School of MedicineDr. Toshihiro ShiraiDepartment of Respiratory Medicine, Shizuoka General Hospital

• Part 1 Concept of Asthma COPD overlap.- 1 Concept of Asthma COPD overlap - Japanese guideline and global trends. How was the concept of Asthma COPD overlap developed and moving forward? .- 2 Concept of treatable traits and ACO (2): Can treatable traits approach be applied into practice? .- Part 2 Epidemiology and Prognosis.- 3 Epidemiology of ACO from global data: Does the prevalence of ACO vary among global analyses? .- 4 Epidemiology of ACO defined by the JRS guidelines. What is the prevalence of ACO in Japan? .- 5 Prognosis and characteristics of ACO: What are the specific characteristics of ACO?- 6 Prognosis of COPD with asthma-like features and ACO: Is the prognosis of COPD and ACO different? .- 7 Causes of death in patients with asthma-chronic obstructive pulmonary disease overlap: Is there any difference compared to asthma?.- Part 3 Pathophysiology of ACO.- 8 Inflammatory phenotypes and potential bio-markers of ACO. What is the specific feature of ACO? .- 9 Role of Nitrosative stress: What is the potential clinical implication?.- 10 Radiographic features of ACO. How the feature is applied into practice?.- 11 Pulmonary Function of ACO: What is the role of the forced oscillation technique?.- 12 Underlying mechanism suggested by the ACO model. What is the lesson learned from the model?.- Part 4 Diagnosis of ACO.- 13 Comparison of diagnostic criteria of ACO: What is the point of difference?.- 14 Role of FeNO - How can FeNO be positioned in practice?.- 15 Role of IgE and Eosinophils: The use of type 2 biomarkers in practice.- 16 Rhinosinusitis in ACO: What is the implication of nasal comorbidity?.- Part 5 Treatment.- 17 Current evidence of treatment for asthma-COPD overlap (ACO): Is there emerging evidence of optimal therapy? .- 18 Potential treatment options for ACO, including biologics: Are there any roles of biologics?.